Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome

Zhang,Jing; Zhou,Lingling; Tang,Liulin; Xu,Liangzhi

doi:10.3892/etm.2014.1556

Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome

Authors:
- Jing Zhang
- Lingling Zhou
- Liulin Tang
- Liangzhi Xu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Obstetrics and Gynecology, People's Hospital of Yicheng, Yicheng, Hubei 441400, P.R. China, Department of Obstetrics and Gynecology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China
Published online on: February 18, 2014 https://doi.org/10.3892/etm.2014.1556
Pages: 1215-1220

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) is a common reproductive endocrinology disease, however, an explicit etiology is not known. Insulin resistance (IR) appears to be central to the pathogenesis of PCOS and inflammation may be significant in the pathogenesis of IR in PCOS. The aims of the present study were to investigate the plasma visfatin level and the gene expression of visfatin in peripheral blood mononuclear cells (PBMCs) and peripheral blood monocyte‑derived macrophages (PBMMs) from PCOS patients, in addition to investigating the association between PCOS and IR. A total of 21 PCOS patients and 21 control subjects were enrolled in the study; the homeostasis model assessment of insulin resistance (HOMA‑IR) was considered to be a stratified method for establishing the subgroups. Fasting blood samples were collected and the levels of sex hormones, insulin, glucose, blood lipids and visfatin were measured. In addition, visfatin gene expression levels in PBMCs and PBMMs were assessed using quantitative polymerase chain reaction. The plasma visfatin and gene expression levels of visfatin in PBMCs and PBMMs were not observed to increase in the normal weight PCOS and normal weight IR patients. Furthermore, plasma visfatin levels did not correlate with the normal weight PCOS patients or the normal weight IR patients per se. Further investigation into the role of visfatin in the pathogenesis of PCOS or IR should examine macrophages in the tissues, rather than macrophages in the peripheral blood.

View Figures

View References

1	Ehrmann DA: Polycystic ovary syndrome. N Engl J Med. 352:1223–1236. 2005. View Article : Google Scholar : PubMed/NCBI
2	Dunaif A and Thomas A: Current concepts in the polycystic ovary syndrome. Annu Rev Med. 52:401–419. 2001. View Article : Google Scholar : PubMed/NCBI
3	Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O and Blumenfeld Z: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 89:2160–2165. 2004. View Article : Google Scholar : PubMed/NCBI
4	Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM and Sattar N: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 86:2453–2455. 2001. View Article : Google Scholar : PubMed/NCBI
5	Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP and Legro RS: Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism. 55:1076–1082. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF and Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 271:665–668. 1996. View Article : Google Scholar : PubMed/NCBI
7	Yudkin JS, Kumari M, Humphries SE and Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 148:209–214. 2000. View Article : Google Scholar : PubMed/NCBI
8	Sun Q, Li L, Li R, et al: Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Ann Med. 41:311–320. 2009. View Article : Google Scholar : PubMed/NCBI
9	Fukuhara A, Matsuda M, Nishizawa M, et al: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 307:426–430. 2005. View Article : Google Scholar : PubMed/NCBI
10	Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M and Lobo RA: Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril. 91(4 Suppl): 1332–1335. 2009. View Article : Google Scholar : PubMed/NCBI
11	Cekmez F, Cekmez Y, Pirgon O, Canpolat FE, Aydinöz S, Metin Ipcioglu O and Karademir F: Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 22:32–37. 2011.PubMed/NCBI
12	Gen R, Akbay E, Muslu N, Sezer K and Cayan F: Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol. 25:241–245. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R and Weerakiet S: Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 25:536–542. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kowalska I, Straczkowski M, Nikolajuk A, et al: Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod. 22:1824–1829. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ozkaya M, Cakal E, Ustun Y and Engin-Ustun Y: Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril. 93:880–884. 2010. View Article : Google Scholar : PubMed/NCBI
16	Plati E, Kouskouni E, Malamitsi-Puchner A, Boutsikou M, Kaparos G and Baka S: Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril. 94:1451–1456. 2010. View Article : Google Scholar : PubMed/NCBI
17	Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR and Randeva HS: Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab. 91:5022–5028. 2006. View Article : Google Scholar
18	Yildiz BO, Bozdag G, Otegen U, et al: Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. Reprod Biomed Online. 20:150–155. 2010. View Article : Google Scholar : PubMed/NCBI
19	Dikmen E, Tarkun I, Cantürk Z and Cetinarslan B: Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol. 27:475–479. 2011. View Article : Google Scholar : PubMed/NCBI
20	Lajunen TK, Purhonen AK, Haapea M, et al: Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest. 42:321–328. 2012. View Article : Google Scholar : PubMed/NCBI
21	Tarkun I, Dikmen E, Cetinarslan B and Cantürk Z: Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw. 21:272–277. 2010.PubMed/NCBI
22	Zwirska-Korczala K, Sodowski K, Konturek SJ, et al: Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol. 59(Suppl 2): 161–178. 2008.PubMed/NCBI
23	Chan TF, Chen YL, Chen HH, Lee CH, Jong SB and Tsai EM: Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril. 88:401–405. 2007. View Article : Google Scholar : PubMed/NCBI
24	Tsiotra PC, Tsigos C, Yfanti E, et al: Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res. 39:758–763. 2007. View Article : Google Scholar : PubMed/NCBI
25	Seow KM, Hwang JL, Wang PH, Ho LT and Juan CC: Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome. Hum Reprod. 26:2869–2873. 2011. View Article : Google Scholar : PubMed/NCBI
26	Peng KH, Xue M and Xiao SS: mRNA expression of visfatin in omentaladipose tissue in polycystic ovary syndrome. Xian Dai Sheng Wu Yi Xue Jin Zhan. 13:2514–2516. 25372009.(In Chinese).
27	Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 81:19–25. 2004. View Article : Google Scholar
28	Chen X, Yang D, Li L, Feng S and Wang L: Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod. 21:2027–2032. 2006. View Article : Google Scholar : PubMed/NCBI
29	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
30	Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R and Bouloumié A: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 49:744–747. 2006.PubMed/NCBI